Clinical Trials Logo

Donor Site Complication clinical trials

View clinical trials related to Donor Site Complication.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06030791 Recruiting - Clinical trials for Anterior Cruciate Ligament Rupture

BTB Graft Harvest and Donor Site Morbidity After ACL Reconstruction

Start date: October 31, 2022
Phase:
Study type: Observational

The aim of this observational study is to examine the connection between bone-tendinous defects after BTB graft harvest and the development of anterior knee pain.

NCT ID: NCT05740033 Recruiting - Oral Cancer Clinical Trials

Radial Forearm Donor Site Closure

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The radial forearm free flap (RFFF) is widely used in head and neck reconstruction. Its thinness, pliability, pedicle length, and vessel size are particularly suited for oropharyngeal and oral cavity reconstruction. Concerns about aesthetic and functional morbidity at the donor site have given rise to various techniques of closing the donor site, two of which are the split-thickness skin graft (STSG), taken from the thigh, and the hatchet flap, which uses a local flap within the radial forearm. This RCT will determine whether retrospectively reported improvements to aesthetic and functional outcomes for STSG patients are greater compared to hatchet flap patients.

NCT ID: NCT04743375 Recruiting - Wound Heal Clinical Trials

Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment

Start date: February 2021
Phase: N/A
Study type: Interventional

To examine the efficacy and safety of sericin dressing with collagen in STSG donor site treatment comparing with Bactigras®. Around 30 patients will be enrolled in this study.

NCT ID: NCT04186273 Recruiting - Scar Clinical Trials

Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.

FS2
Start date: December 5, 2019
Phase: Phase 2
Study type: Interventional

The study will investigate the safety and effectiveness of daily post surgical scar management, using a moisture-balancing base product containing different amounts of a novel (NCE) antifibrogenic compound FS2, a natural metabolite of the kynurenine pathway. Results of recent peer-reviewed, pre-clinical evidence warrant further investigation to validate therapeutic scar preventive efficacy of topically administered/delivered FS2. There are no known safety concerns with current product formulations. Recent Phase I clinical safety and tolerability data further support continuation of the research proposed in this study.